Interactions of Epidermal Growth Factor Receptor Inhibition with DNA damage in the treatment of gastrointestinal cancer

Add to your list(s) Download to your calendar using vCal

• Prof Daniel Hochhauser, University College London
• Tuesday 14 September 2010, 12:00-13:00
• CRI Lecture Theatre.

If you have a question about this talk, please contact Mala Jayasundera.

There has been extensive development of targeted therapies for treatment of cancer. These include antibodies and small molecules which inhibit pathways essential for cancer cell proliferation and metastasis. An important example is the epidermal growth factor receptor (EGFR) pathway which is the target of antibodies (cetuximab, panitumumab) and small molecules (gefitinib, erlotinib) used clinically. Although specific EGFR mutations found in lung cancer result in significant sensitivity to gefitinib and erlotinib, the response to single agents has been modest. Preclinical evaluation has suggested synergy between chemotherapy and radiation when combined with EGFR inhibition. However this has not generally translated into clinical benefit. In this presentation the possible mechanisms of these interactions will be outlined, together with suggestions for design of optimal combinations of EGFR inhibitors and chemotherapy, using gastrointestinal cancer as an example.

This talk is part of the Cambridge Oncology Seminar Series series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biology
• CCC talks for website
• CRI Lecture Theatre
• CRUK CI Seminars
• Cambridge Oncology Seminar Series
• Life Sciences
• Life Sciences
• ME Seminar
• MRC Cancer Unit Seminars
• PMRFPS's
• cancer
• cri
• my_list
• other talks
• se393's list
• sfm36

Note that ex-directory lists are not shown.